BPC-157
Also known as: Body Protection Compound 157, PL 14736, Bepecin
A synthetic 15-amino-acid peptide with striking tissue-healing effects in rodent studies — and essentially no controlled human evidence. Sold as a research chemical, not an approved drug.
Not approved by the FDA for any use. Sold for laboratory research only. FDA placed BPC-157 in category 2 of its interim compounding policies — bulk drug substances that may present significant safety risks — citing immunogenicity risk for certain routes, peptide-related impurities and API characterisation difficulty, and no or only limited safety data; the nomination was subsequently withdrawn by the nominator. FDA's Pharmacy Compounding Advisory Committee took BPC-157 up again on 23 July 2026 for possible inclusion on the 503A Bulks List.
What it is
BPC-157 is a synthetic 15-amino-acid peptide derived from a sequence found in human gastric juice. In animal research it has shown a broad, almost implausibly wide range of tissue-protective and healing effects. It is one of the most-searched “research peptides” — and one where the gap between online claims and actual human evidence is widest.
What it’s approved or studied for
Nothing. BPC-157 is not approved by the FDA for any use and is sold for laboratory research only. Nearly all of the supporting data come from rodent studies. There are no adequate, controlled human trials establishing that it works or that it is safe.
What human evidence exists
Effectively none of the controlled kind. The healing claims — tendon, ligament, gut, muscle — rest on Grade D preclinical evidence: animal, cell, and mechanistic studies. That evidence is genuinely interesting and consistent enough to justify human trials, but it does not establish effectiveness or safety in people. Long-term human safety is Grade U: unknown.
The major unknowns
Human pharmacokinetics, effective dose, long-term safety, and whether any of the rodent benefits translate to humans are all open questions. Compound purity is a further problem: research-chemical supply is unregulated, so what’s in a given vial is uncertain.
Most important safety considerations
Because there is no controlled human safety data, the honest answer to “is it safe?” is that no one knows. Product quality is uncontrolled, it is prohibited in sport under WADA’s S0 category, and it is not a legal therapeutic. This page summarizes the research record; it is not medical advice or an endorsement of use.
Evidence by outcome
Each outcome is graded on its own evidence — a compound can be strong for one use and unproven for another. See how we grade.
Promising in rats; not demonstrated in humans. — Multiple rodent studies report accelerated tendon-to-bone healing and fibroblast activity, but no controlled human trials confirm this.
Animal data only. — Rodent models show protection against NSAID- and stress-induced gastrointestinal injury; human evidence is anecdotal.
Preclinical signal, no human confirmation.
Unknown — no controlled human safety data exist.
Safety
Common adverse effects
- Not established in humans; injection-site reactions reported anecdotally
Serious risks
- Unknown — no controlled human safety data; unregulated product quality and contamination risk
Contraindications
- No human contraindication data; not approved for human use
References
- Sikiric P et al. Stable Gastric Pentadecapeptide BPC 157 — review of tissue-healing research. Current Pharmaceutical Design (2018)
- FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (category 2; lists BPC-157)
- FDA. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (BPC-157 free base and acetate; use evaluated: ulcerative colitis)